Abstract:Brain edema is one of the fatal pathologies after subarachnoid hemorrhage (SAH). Previous research suggested that increased microvascular permeability might be a primary contributor to brain edema. Normally, the vascular endothelial barrier is maintained by 2 key junctions between endothelial cells, tight junctions (TJs), and adherens junctions (AJs). In the past 2 decades, much attention has been paid to the involvement of TJs in the increased vascular permeability after SAH. However, the integrity of AJs is also critical in maintaining microvascular permeability, and disruption of AJs can lead to interstitial edema. AJs comprise transmembrane protein vascular endothelial (VE)-cadherin and α-, β-, γ-, and δ-catenins in the cytoplasm. Inhibition of VE-cadherin by homophilic binding resulted in increased microvascular permeability. Protease-activated receptor-1, -3, and -4 (PAR-1, 3, and 4, but not PAR-2) are thrombin receptors, which are a subfamily of G-protein–coupled receptors. PAR-1 is a major receptor on the endothelial cells. PAR-1 activation increases the activity of downstream protein kinases, such as c-Src and p21activated kinase-1 (PAK1), which leads to phosphorylation of key target proteins. Before PAR-1 orchestrates its actions, it must be activated by thrombin, which increased in plasma after SAH. Although PAR-1 activation could lead to cerebral vasospasm, its role in increasing microvascular permeability after SAH is not clear yet. Background and Purpose—Plasma thrombin concentration is increased after subarachnoid hemorrhage (SAH). However, the role of thrombin receptor (protease-activated receptor-1 [PAR-1]) in endothelial barrier disruption has not been studied. The aims of this study were to investigate the role of PAR-1 in orchestrating vascular permeability and to assess the potential therapeutics of a PAR-1 antagonist, SCH79797, through maintaining vascular integrity. Methods—SCH79797 was injected intraperitoneally into male Sprauge-Dawley rats undergoing SAH by endovascular perforation. Assessment was conducted at 24 hours after SAH for brain water content, Evans blue content, and neurobehavioral testing. To explore the role of PAR-1 activation and the specific mechanism of SCH79797’s effect after SAH, Western blot, immunoprecipitation, and immunofluorescence of hippocampus tissue were performed. A p21activated kinase-1 (PAK1) inhibitor, IPA-3, was used to explore the underlying protective mechanism of SCH79797. Results—At 24 hours after SAH, animals treated with SCH79797 demonstrated a reduction in brain water content, Evans blue content, and neurobehavioral deficits. SCH79797 also attenuated PAR-1 expression and maintained the level of vascular endothelial-cadherin, an important component of adherens junctions. Downstream to PAR-1, c-Src–dependent activation of p21-activated kinase-1 led to an increased serine/threonine phosphorylation of vascular endothelialcadherin; immunoprecipitation results revealed an enhanced binding of phosphorylated vascular endothelial-cadherin with endocytosis orchestrator β-arrestin-2. These pathological states were suppressed after SCH79797 treatment. Conclusions—PAR-1 activation after SAH increases microvascular permeability, at least, partly through a PAR-1-c-Srcp21-activated kinase-1-vascular endothelial-cadherin phosphorylation pathway. Through suppressing PAR-1 activity, SCH79797 plays a protective role in maintaining microvascular integrity after SAH. (Stroke. 2013;44:1410-1417.)

Fc-saxatilin suppresses hypoxia-induced vascular leakage by regulating endothelial occludin expression

Fc-saxatilin inhibits VEGF-induced permeability by regulating claudin-5 expression in human brain microvascular endothelial cells

Pannexin1 Channel Inhibitor (10panx) Protects Against Transient Focal Cerebral Ischemic Injury by Inhibiting RIP3 Expression and Inflammatory Response in Rats.

Saxatilin, a Snake Venom Disintegrin, Regulates Platelet Activation Associated with Human Vascular Endothelial Cell Migration and Invasion

The Protective Effects of Axitinib on Blood-Brain Barrier Dysfunction and Ischemia-Reperfusion Injury in Acute Ischemic Stroke

Activating NO–sGC Crosstalk in the Mouse Vascular Niche Promotes Vascular Integrity and Mitigates Acute Lung Injury

Release of Matrix Metalloproteinases-2 and 9 by S-Nitrosylated Caveolin-1 Contributes to Degradation of Extracellular Matrix in Tpa-Treated Hypoxic Endothelial Cells

Unlocking endothelial barrier restoration: FX06 in systemic capillary leak syndrome and beyond

Vitexin regulates Epac and NLRP3 and ameliorates chronic cerebral hypoperfusion injury

The tight junction protein occludin modulates blood–brain barrier integrity and neurological function after ischemic stroke in mice

An oxygen-adaptive interaction between SNHG12 and occludin maintains blood-brain barrier integrity

XAV939 Inhibits Intima Formation by Decreasing Vascular Smooth Muscle Cell Proliferation and Migration Through Blocking Wnt Signaling

Glycocalyx is critical for blood‐brain barrier integrity by suppressing caveolin1‐dependent endothelial transcytosis following ischemic stroke

Antagonizing Αvβ3 Integrin Improves Ischemia-Mediated Vascular Normalization and Blood Perfusion by Altering Macrophages.

A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling

Lipocalin 10 is essential for protection against inflammation-triggered vascular leakage by activating LRP2-Ssh1 signaling pathway

VE-cadherin Role of SCH 79797 in Maintaining Vascular Integrity in Rat Model of Subarachnoid Hemorrhage

Galangin Inhibits Thrombin-Induced MMP-9 Expression in SK-N-SH Cells via Protein Kinase-Dependent NF-κB Phosphorylation

Protective Role of Endothelial SIRT1 in Deep Vein Thrombosis and Hypoxia-induced Endothelial Dysfunction Mediated by NF-κB Deacetylation

CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury

Protection of Tight Junctional Complexes between hCMEC/D3 Cells by Deep-Sea Fibrinolytic Compound FGFC1